The FDA has granted orphan drug designation to the oral agent OPN-6602 for the treatment of patients with relapsed or ...

Idecabtagene vicleucel induced high complete response and minimal residual disease negativity rates in multiple myeloma after ...

Throughout my experience with multiple myeloma, I was humbled by the unexpected support and kindness shown to me.

Although the treatment of myeloma has changed dramatically after the readout of many recent trials, key unanswered questions ...

In a Community Case Forum in partnership with the North Carolina Oncology Association, Cristina Gasparetto, MD, discussed the CEPHEUS, IMROZ, and BENEFIT trials of treatment for transplant-ineligible ...

Linvoseltamab is an investigational B-cell maturation antigen CD3-targeted bispecific antibody. The BLA resubmission was needed as the original application could not be approved due to manufacturing ...

Firefighters, police officer who responded to 9/11 in World Trade Center do have an increased risk of multiple myeloma. There are some other well-defined occupational exposures. For instance ...

A five-year study has found that adding daratumumab (D) to the current standard-of-care triplet therapy bortezomib, lenalidomide, and dexamethasone (VRd) produced deeper and more durable minimal ...

Regeneron, which is seeking FDA approval of linvoseltamab for adults with relapsed/refractory multiple myeloma that has progressed after at least three prior therapies, said the agency set a new ...

Researchers sought to identify prognostic factors for survival in patients with newly diagnosed multiple myeloma.

Researchers sought to determine whether teclistamab would lead to a clinical response in patients with relapsed/refractory multiple myeloma.